1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Cell Source, Inc.

Cell Source, Inc.

CLCS
Cell Source, Inc.US flagOther OTC
0.80
USD
-0.06
- -
36.03MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
-0.14
-0.18
-0.1
-0.04
-0.12
-0.09
-0.18
-0.19
-0.19
-0.18
-0.17
- -
-0.14
Free Cash Flow per Basic Share
- -
-0.07
-0.14
-0.08
-0.06
-0.09
-0.07
-0.09
-0.1
-0.1
-0.09
-0.06
- -
-0.06
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-0.3
-0.36
-0.41
-0.44
-0.54
-0.6
-0.75
-0.88
-0.94
-1.04
-1.1
- -
-1.12
Tangible Book Value per Share
- -
-0.05
-0.17
-0.22
-0.24
-0.17
-0.18
-0.2
-0.27
-0.3
-0.36
-0.41
- -
-0.45
Basic Weighted Avg Shares
- -
13
22
26
26
27
28
28
29
33
35
38
- -
41
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-2
-4
-3
-1
-3
-2
-4
-5
-5
-5
-5
-5
-5
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
-1
-4
-6
-6
-5
-5
-6
-8
-10
-13
-16
-19
-19
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
-1
-4
-6
-6
-5
-5
-6
-8
-10
-13
-16
-19
-19
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
10
10
10
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
42
43
45
Market Capitalization
- -
13
14

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
18
19
19
Payables & Accruals
6
7
7
ST Debt
10
10
10
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.12%
26.59%
18.74%
Free Cash Flow
1.96%
2.21%
14.32%
Net Income, GAAP
20.3%
0.82%
-15.2%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
13.24%
11.92%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.05
-0.04
-0.04
- -
-0.18
2023
-0.05
-0.04
-0.04
- -
-0.17
2024
-0.04
-0.04
-0.04
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Itamar Shimrat
Full Time Employees
1
Sector
Healthcare
Industry
Biotechnology
Address
57 West 57th Street New York City NY United States of America 10019
IPO Date
May 1, 2014
CIK
0001569340
Website
cell-source.com
Similar Companies
Zevra Therapeutics, Inc. (ZVRA)
Pasithea Therapeutics Corp. (KTTAW)
Sol-Gel Technologies Ltd. (SLGL)
Sangamo Therapeutics, Inc. (GBY.DE)
Arcturus Therapeutics Holdings Inc. (ARCT)
Abliva AB (publ) (ABLI.ST)
Business
Cell Source, Inc. (CLCS) is a biotechnology company that develops cell therapy treatments based on immune tolerance management through its proprietary Veto Cell technology; this platform enables selective blocking of immune responses to facilitate safer allogeneic stem cell transplantation, organ transplants, and cancer therapies including Veto CAR-T cells for leukemia, lymphoma, and multiple myeloma; additional applications target non-malignant diseases such as type-1 diabetes, sickle-cell anemia, and multiple sclerosis via bone marrow transplantation with Veto Cells. The company, founded in 2011 and headquartered at 57 West 57th Street, Suite 400, New York, NY, operates primarily in the immunotherapy sector with a subsidiary in Tel Aviv, Israel, and focuses on therapeutic areas encompassing blood cancers, hematologic conditions, solid organ transplantation, and autoimmune disorders. In December 2024, Cell Source presented preclinical data on its off-the-shelf Veto CAR-T cell therapy at the American Society of Hematology Annual Meeting, highlighting potential breakthroughs in immune tolerance for next-generation cancer treatments. Earlier milestones include a 2014 acquisition of Cell Source (Israel) Ltd. and $3.6 million private placement to fund clinical advancement, alongside a 2015 convertible note financing of $3 million.

Company News

APIChatGPT

  • accessnewswire.com

    Cell Source Presented Its Breakthrough Developments for Mismatched Donor Stem Cell and Organ Transplants and Off-the-shelf CAR-T Cell Therapy at the LD Micro Invitational Conference in Los Angeles This Week

  • newsfilecorp.com

    Cell Source, Inc. to Present at the LD Micro Invitational XVI

  • accessnewswire.com

    Cell Source Announces Closing of Private Placement and Hiring of Transfer Agent